Rapiblyk® Powder for Injection for Infusion (landiolol hydrochloride)

Rapiblyk^® Powder for injection for infusion contains 300 mg landiolol hydrochloride (equivalent to 280 mg landiolol) supplied as a 50 mL glass vial.

Indication:
Rapiblyk^® is indicated in adults for: Supraventricular tachycardia and for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable. Non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention. Rapiblyk^® is not intended for chronic use.